Subtype
Lung Neuroendocrine Neoplasm
CI-CAN-00001096Explore in graph →
Non-malignant399 active trials6 approved drugs6 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001096Explore in graph →
Clinical trials
1,149 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04507919 | Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
| NCT03503890 | Expanded Access to Rovalpituzumab Tesirine | no longer available | — | — | AbbVieINDUSTRY | 0 | Sep 10, 2019 |
| clinicaltrials |
Data updated 22 days agoSource updated Nov 12, 2024source: clinicaltrials